group of patients with myasthenia gravis or 'myasthenia gravis like' syndromes was made.
Methods The study group consisted of patients who had undergone botulinum toxin treatment and/or surgery for disabling diplopia, poor cosme sis or both. Surgical treatment was by conventional techniques including recess/resect, posterior fixation, superior oblique tenotomy and adjustable sutures.
Results There were 9 patients in the study group (8 Our aim was to study, partly retrospectively, a group of patients with myasthenia gravis or myasthenia gravis like syndromes who had undergone extraocular muscle surgery and/or botulinum toxin treatment.
Materials and methods
The study group consisted of patients identified from a large botulinum toxin database (>4000 
Results
There were nine patients in the study group (8 female; 1 male). Age at presentation ranged from 21 to 59 years (mean 46 years). The study group divided conveniently into three treatment groups, namely toxin only (3 cases), surgery only (3 cases) and combined toxin and surgery (3 cases).
In the toxin only group, 2 patients were symptom-free with maintenance injections of botulinum toxin. The interval between treatments varied between 6 and 12 I months. One patient, despite repeated injections, could not achieve satisfactory alignment and declined surgery. To relieve disabling diplopia she was fitted with an occlusive contact lens. Three patients underwent surgery alone; 1 of these was symptom free post-operatively, while 2 patients required a prism for control. The 3 remaining patients reqUired a combination of surgery and toxin injections. Of these, 1 patient was satisfactorily aligned while 2 had occasional diplopia but were symptomatically improved. In all cases follow-up was for a minimum of 6 months (mean follow-up 20 months after treatment). The cases are summarised in the Tables 1 and 2 . Cases 4 and 6 are described in more detail below. Fig. 1 . Case 6 was a 55-year-old woman who presented with a 10 year history of vertical diplopia and fatiguable ptosis. Previously she had some evening fatiguability but at the time of surgery she had been free of systemic symptoms for upwards of 18 months. Her diplopia was initially controlled with prisms but with increasing • ..
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Leh-E • Fig. 1 . Case 4. Pre-and post-operative Hess charts following left superior rectus recession.
disease activity an occlusive contact lens had been fitted. This approach had limited success for 5 years. Her symptoms were improved with pyridostigmine; however, this was not tolerated due to a previous ileostomy for severe ulcerative colitis. At the time of referral she had a left hypertropia of 20 prism dioptres at near and 18 prism dioptres for distance, with associated left inferior rectus under action. A left inverse Knapp procedure was performed, following which she had a left hyperphoria of 4 prism dioptres for near and 2 prism dioptres for distance (her pre-and post-operative appearance is shown in Fig. 2 ). This realignment resulted in an asymptomatic patient with stereopsis of 100 seconds of arc at her first post-operative visit. Following her most recent assessment she required a small prism and was asymptomatic with good control.
Complications
Botulinum toxin injections are not free from side-effects. This was demonstrated in case 3. This 57-year-old woman was diagnosed with myasthenia gravis at the age of 14 years. Her generalised weakness was relatively well controlled on pyridostigmine. Her ocular status preoperatively was a decompensating exophoria of 45 prism dioptres with left hyperphoria of 18 prism dioptres for near and distance. She underwent right inferior rectus and bilateral lateral rectus botulinum toxin injections under electromyographic control. Following this she maintains good control of an exophoria which measures 10 and 4 prism dioptres base in, near and distance respectively, with a small left hyperphoria. She continues to be satisfactorily controlled with maintenance toxin injections to both lateral recti at 6 monthly intervals. Following her most recent treatment with toxin she developed a left ptosis with an associated left hypotropia which resolved within 3 months. Systemic treatment remained unchanged following our interventions in all patients.
Discussion
It is apparent from the small numbers generated by our research of a large database that extraocular muscle surgery and/ or botulinum toxin therapy is not appropriate in most cases where continued disease activity exists. It is of interest that Oosterhuis, 8 in a study of 58 myasthenics, found more than 50% of long-term survivors were in remission. Not surprisingly then, there appears to be a small subgroup of myasthenics who had a stable oculomotor problem leaving open options for non-systemic treatments. Acheson and co-workers 4 described 5 cases ranging from age 16 to 52 years with a 4:1 male preponderance, all positive for acetylcholine receptor antibodies. All their cases had been stable for at least 2 years prior to surgery and had constant diplopia. Four of these five cases were exotropic prior to surgery. They described mainly horizontal rectus recess/resect procedures with superior oblique posterior tenotomy in 2 cases. Follow-up was from 6 months to 6 years, and all patients were described as having a significantly increased field of binocular single vision. cases with myasthenia based on clinical grounds and a positive tensilon test (anti-acetylcholine receptor antibodies were not detected in any of their cases). Three of their four cases were exotropic and all underwent horizontal recess/resect procedures with reported improvement of both ocular alignment and diplopic symptoms in all cases. One case was noted to have recurrent exotropia within 2.5 years. The only remaining paper, that we are aware of, on this topic is that by Ohtsuki and co-workers? who operated on 4 patients and had good results in 3. They made electron microscopic studies of resected muscles and noted non-specific degenerative changes and sarcomeric disorganisation compared with controls. This literature review thus includes 19 cases where surgical intervention has been reported in patients with stable ocular motility signs with varying degrees of success. In this series we have added 9 further cases managed both surgically and with botulinum toxin. Our success rates compare favourable with those reported above. It is apparent from our use of botulinum toxin that it has a role to play in the treatment of ocular myasthenia and to our knowledge this has not been previously reported.
Myasthenia gravis and its treatment is a topic of intense research, particularly in the area of cell-mediated autoimmunity. We look forward to a time when systemic therapy will help these patients, perhaps avoiding surgery altogether. 9
Summary
From our data patients with myasthenia gravis and stable ocular motility signs should be considered for active management, namely botulinum toxin, muscle surgery or a combination of both.
We are grateful to Miss G. W. Adams for the opportunity to report one of her cases.
